Luis Hernandez, MD
Interventional Pain Medicine · Thibodaux, LANPI 1932130143
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,202 of the $2,837 with a category attached, or 77.6%. 32 manufacturers reported payments, led by SPR Therapeutics, Inc at 26.5% of the total. Reporting peaked in 2024 at $1,122 and has fallen 96.4% since, to $40 in 2025. That places this record below the midpoint for interventional pain medicine clinicians in LA, where the typical reported total is $4,761.
Across 131 payments — averaging $21.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- SPR Therapeutics, Inc$752
- Boston Scientific$365
- Amgen$240
- AbbVie$238
- Collegium Pharmaceutical, Inc.$186
- Abbott$138
- plus $919 from 26 others
What the payments were for
- Travel & lodging$63522%
- Food & beverage$2,20278%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| SPR Therapeutics, Inc | 4 | $752 |
| Boston Scientific | 18 | $365 |
| Amgen | 12 | $240 |
| AbbVie(2 entities) | 14 | $238 |
| Collegium Pharmaceutical, Inc. | 9 | $186 |
| Abbott | 7 | $138 |
| Medtronic | 14 | $109 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $92 |
| Sentynl Therapeutics, Inc. | 6 | $76 |
| Pfizer | 4 | $66 |
| Novartis | 3 | $55 |
| Nevro Corp. | 2 | $48 |
| Eisai Inc. | 3 | $48 |
| Teva Pharmaceuticals USA, Inc. | 4 | $47 |
| Zyla Life Sciences, Inc. | 2 | $46 |
| Redhill Biopharma Inc. | 3 | $43 |
| Arbor Pharmaceuticals, Inc. | 3 | $37 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $23 |
| Spinal Simplicity, LLC | 1 | $21 |
| Relievant Medsystems, Inc. | 1 | $21 |
| Averitas Pharma Inc. | 1 | $21 |
| Si-bone, Inc. | 1 | $18 |
| Kowa Pharmaceuticals America, Inc. | 1 | $17 |
| Globus Medical | 1 | $17 |
| Acacia Pharma Inc | 1 | $16 |
| Convatec Inc. | 1 | $16 |
| Almatica Pharma LLC | 1 | $15 |
| Scilex Pharmaceuticals Inc. | 1 | $14 |
| Virtus Pharmaceuticals LLC | 1 | $14 |
| Valinor Pharma, LLC | 1 | $13 |
| Bioventus LLC | 1 | $13 |
| Currax Pharmaceuticals LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,837 in reported general payments places this provider in the 30th percentile of 57 interventional pain medicine providers in Louisiana.
See all interventional pain medicine providers in Louisiana →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BelbucaBuprenorphine Hcl | 36 | $23,363 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 647 | $19,428 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 496 | $15,033 |
| Gabapentin | 409 | $6,285 |
| Tizanidine Hcl | 171 | $1,931 |
| Oxycodone Hcl | 104 | $1,633 |
| Pregabalin | 126 | $1,519 |
| Cyclobenzaprine Hcl | 139 | $1,143 |
| Tramadol Hcl | 83 | $1,071 |
| Lidocaine | 11 | $853 |
| Fentanyl | 13 | $737 |
| Amitriptyline Hcl | 33 | $690 |
| Duloxetine Hcl | 51 | $572 |
| Ibuprofen | 38 | $548 |
| Celecoxib | 41 | $477 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Belbuca | $186 | $23,36336 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 57 interventional pain medicine providers in Louisiana.
Other interventional pain medicine in Thibodaux
- Ashley PeairsThibodaux$17K
- Elizabeth MortazaviThibodaux$7K
- Maged GuirguisNew Orleans$565K
- Suneil JollyKenner$107K
- John CefaluShreveport$71K
- Steve LeeSlidell$57K
- William WhyteShreveport$39K
- Paul HubbellMetairie$33K
- Ken EhrhardtHammond$22K
- Thomas BerryLacombe$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.